Navigation Links
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
Date:3/10/2008

Monogram Assays to be used by Avexa to select patients and optimize

background therapy in phase III program

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that the Company has signed an agreement with AVEXA Limited (ASX: AVX) to be the exclusive provider of HIV resistance and tropism testing technology in support of Avexa's drug discovery and development programs.

Avexa plans to use Monogram's assays across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa plans to use Monogram's PhenoSense(TM) GT assay to select patients and optimize background therapy for trials involving approximately 2,000 patients, and to monitor response to drug treatment during the trials. ATC is a new nucleoside analog that is intended for use in patients who have developed viral resistance to existing drugs. Avexa also has HIV drugs in early development in the CCR5- and integrase- inhibitor classes.

"We are pleased to have selected Monogram as the exclusive provider of resistance tests for our development programs," said Julian Chick, Avexa's chief executive officer. "Monogram has an impressive portfolio of tests that we believe provide the accuracy and reliability that are necessary for studies that are intended to be submitted to the FDA and other regulatory agencies."

"Monogram's phenotypic resistance tests to optimize background therapy helped contribute to successful clinical trials for bo
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 The College of ... private college in the Mid-Hudson Region to be designated ... begin accepting applications from qualified “high-technology” businesses that align ... very pleased to have been selected for the START-UP ... transformative initiative to stimulate economic development in New York ...
(Date:8/21/2014)... 21, 2014  Four-dimensional (4-D) printing develops materials ... external stimuli such as changes in temperature. This ... effect in multiple industries.  In the near future, ... printing objects ranging from human organs to parts ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
Breaking Biology Technology:The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2
... ANGELES, March 5 Vista Partners announced today,that ... $3.52 price target on Inovio,Biomedical Corporation (Amex: ... regarding the ability of their technology to significantly,enhance ... human results,from three independent clinical studies. The company,s ...
... March 5 , - A New Step Forward ... Administration in Acute Coronary Syndrome Patients, Sanofi-aventis (EURONEXT: ... BMY ) announced today that the Committee for Medicinal,Products ... Agency,(EMEA) has issued a positive opinion recommending approval of ...
... SilOnIS shared the 2007 Jean-Pierre Noblanc ... sustainable project in the EUREKA MEDEA+,microelectronics Cluster. ... and mobile multimedia applications that makes life ... value for network operators. SilOnIS combines strained ...
Cached Biology Technology:Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 3New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 4MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... a key region in the global oceanic circulation. "On the ... Atlantic water flows to the north into the Arctic Ocean ... sea ice push their way out of the Arctic into ... cools here on its way to the north and sinks ... this manner drives the global band of oceanic currents like ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... is an intimate and complex relationship between inflammation and cancer; ... chemicals that attract host cells which drive inflammation and help ... by Cell Press in the June issue of the journal ... required for trafficking of immune cells involved in inflammation. ...
... (Minority Access to Research Careers) Program has announced the ... (AAI) Advanced Course in Immunology at The University of ... 2011. These awards are meant to promote the ... the mainstream of the basic science community and to ...
... has been solved with the discovery that the tiny 3 ... use the same buoyancy control as whales. Reporting this ... from British Antarctic Survey describe how Southern Ocean copepods ... deep ocean during winter when seas are stormy and food ...
Cached Biology News:Blocking common gateway to inflammation suppresses cancer 2